Streetbeat News

SKYE

Skye Bioscience Inc

https://www.emeraldbio.life/

CEO

Brian Murphy

Employees

11

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.

Open

2.49

Mkt cap

75M

Volume

3.9K

High

2.52

P/E Ratio

4.64

52-wk high

17.65

Low

2.44

Div yield

N/A

52-wk low

2.31

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:35 pm

U.S. stocks edged lower with the Dow Jones falling 50 points. FedEx reported weaker-than-expected earnings and lowered its full-year guidance, impacting its stock negatively. Meanwhile, Banzai International, Battalion Oil, and Expion360 saw significant stock price increases due to corporate actions.

Portfolio Pulse from Avi Kapoor

September 20, 2024 | 1:46 pm

JMP Securities has initiated coverage on Skye Bioscience with a Market Outperform rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 10:01 am

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 1:01 pm

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 2:14 pm

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:00 pm

Skye Bioscience shares rose as the company began screening patients for a Phase 2 clinical trial of nimacimab.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 12:06 pm

Skye Bioscience has initiated patient screening for a Phase 2 trial of Nimacimab, a weight loss therapeutic for obese patients. Interim data is expected in Q2 2025, with final results in Q4 2025.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 11:06 am

Skye Bioscience (NASDAQ:SKYE) reported Q2 2024 GAAP EPS of $(0.20), beating the analyst consensus estimate of $(0.24) by 16.67%. This represents a 75% improvement over the $(0.80) per share loss from the same period last year. The company also reported a cash position of $74.1 million.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 6:14 am

Beacon Biosignals has announced a strategic collaboration with Skye Bioscience to enhance the upcoming CBEYOND Phase 2 clinical trial of Nimacimab.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 11:34 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.